Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

From Oncology Today with Dr Neil Love Dr. Neil Love

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

CME information and select publications here.

Community discussion

Join the conversation

Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

You May Also Like

Cryptids Of The Corn

Arroe Collins Forest Stories

Real Ghost Stories Online

Tommy Cullum's Let's Get Freaky

Dumma Människor

The Rest Is Science

Vedanta Cast

Mundo Insólito Radio

This Week in Microbiology

The Grave Talks | Haunted, Paranormal & Supernatural